NEW YORK, Sept. 18, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the appointment of Corey Sohmer to the position of Vice President of Finance and Business Development. Mr. Sohmer will be responsible for directing Actinium's accounting, finance and investor relations functions as well as supporting capital raising and business development activities.
"Corey has a broad financial background in the biotech industry. He brings leadership experience relevant to all key aspects of Actinium's corporate development, including financing, accounting, investor relations and public reporting," said Kaushik J. Dave, Ph.D., MBA, President and CEO of Actinium. "Corey will be an extremely valuable addition to the Actinium team as we continue to progress the Company's lead candidates Iomab-B and Actimab-A."
"I am excited to join the Company at a pivotal point in its growth and look forward to contributing to its future success," said Mr. Sohmer. Prior to joining Actinium, Mr. Sohmer served in a variety of core finance and business development functions over the span of twelve years at three NASDAQ listed biopharmaceutical companies. Most recently, Mr. Sohmer was the Director Corporate Finance at Cyclacel Pharmaceuticals, Inc. for six years. Before joining Cyclacel, he was the Senior Director of Financial Planning and External Reporting at EpiCept Corporation and Manager of Finance and Business Development at Pharmos Corporation. He has more than 20 years of finance and accounting experience. Mr. Sohmer holds a Masters in Business Administration and a Bachelors of Science degree in Accounting from Bentley University.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) is a New York based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha emitting actinium-225 and bismuth-213 radiopharmaceuticals in conjunction with monoclonal antibodies. The Company also develops other radiopharmaceuticals for select applications.
For more information:
Visit our web site www.actiniumpharmaceuticals.com
Dennis S. Dobson Jr.
Tel: (203) 258-0159
Actinium Pharmaceuticals, Inc.
Investor/Media Relations: Corey Sohmer, (646) 459-4201
Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
|SOURCE Actinium Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved